How GLP-1, GIP and Glucagon Triple Agonism Affects Energy Expenditure: Mechanisms and Research Evidence

Triple agonism of GLP-1, GIP, and glucagon receptors increases energy expenditure through multiple complementary mechanisms, including enhanced thermogenesis, brown adipose tissue activation, and elevated resting metabolic rate. This pharmacological approach, exemplified by retatrutide, represents a fundamental shift from single-pathway GLP-1 agonists by directly influencing how the body burns calories rather than solely reducing caloric intake.

Distinct Roles of Each Receptor Pathway

Understanding how each component contributes to energy balance clarifies why their combination proves synergistic. GLP-1 receptor activation primarily reduces appetite and slows gastric emptying, with modest direct effects on thermogenesis (Finan 2015). GIP receptor signaling enhances insulin secretion in a glucose-dependent manner and may improve lipid clearance, though its independent role in energy expenditure remains less defined (Coskun 2022). Glucagon receptor activation directly stimulates hepatic glucose production and increases energy expenditure through enhanced thermogenic activity, particularly in brown adipose tissue (BAT).

The inclusion of glucagon activity distinguishes triple agonists from dual GLP-1/GIP agonists like tirzepatide. Glucagon's calorigenic effect—historically recognized but difficult to harness therapeutically due to hyperglycemic risk—becomes viable when counterbalanced by GLP-1's insulinotropic and glucagonostatic properties. This balanced polypharmacology permits glucagon's metabolic benefits without unacceptable glucose perturbation.

Thermogenesis and Brown Adipose Tissue Activation

Preclinical studies demonstrate that glucagon receptor agonism activates BAT thermogenesis through cAMP-dependent signaling pathways. Brown adipocytes express abundant glucagon receptors, and their stimulation triggers mitochondrial uncoupling protein 1 (UCP1) activation, dissipating energy as heat rather than ATP production. Research in rodent models shows that combined GLP-1/glucagon agonists increase BAT temperature and whole-body oxygen consumption more effectively than GLP-1 agonism alone.

Human BAT activation by glucagon has been confirmed using PET-CT imaging, with measurable increases in glucose uptake and metabolic activity in supraclavicular BAT depots. The triple agonist design leverages this biology while the GLP-1 and GIP components protect against glucagon-mediated hyperglycemia. Whether the magnitude of BAT activation in humans achieves clinical significance for weight loss independent of reduced energy intake remains under active investigation.

Hepatic and Systemic Metabolic Effects

Beyond BAT, triple agonism influences energy expenditure through hepatic mechanisms. Glucagon increases hepatic fatty acid oxidation and ketogenesis, processes that consume ATP and generate heat. The hormone also elevates hepatic energy expenditure through futile cycling of metabolic intermediates—simultaneously activating opposing pathways that net no productive output but consume ATP.

GLP-1 contributes through its effects on glucose effectiveness and potential enhancement of glucose uptake in peripheral tissues. The GIP component may improve metabolic flexibility, facilitating the switch between carbohydrate and lipid oxidation. Together, these pathways create a metabolic environment favoring increased energy outflow, though quantifying this contribution relative to reduced energy intake presents methodological challenges in human trials.

Clinical Evidence from Retatrutide Development

Phase 1-2 data for retatrutide (LY3437943) provide indirect evidence for enhanced energy expenditure. In dose-ranging studies, weight loss exceeded that predicted by caloric restriction alone, suggesting additional metabolic effects (Rosenstock 2023). Participants achieved mean weight reductions of up to 8.2% at 12 weeks at the highest doses tested—substantially greater than anticipated from comparable GLP-1 monotherapy at similar timepoints.

Indirect calorimetry substudies in related triple agonist programs have reported increased resting energy expenditure compared to placebo, though data specific to retatrutide remain limited in peer-reviewed literature. The SURMOUNT and STEP trial frameworks, established for tirzepatide and semaglutide respectively, provide benchmarks against which retatrutide's additional glucagon-mediated effects may eventually be quantified. Head-to-head trials will be necessary to isolate the energy expenditure contribution from the combined pharmacology.

Methodological Considerations in Measurement

Accurately measuring energy expenditure effects of triple agonism presents significant challenges. Standard approaches include whole-room indirect calorimetry, doubly labeled water methods, and activity monitors, yet each has limitations when applied to pharmacological interventions that simultaneously alter intake, gastrointestinal function, and metabolic rate. The confounding effect of reduced food intake itself lowers the thermic effect of food, potentially masking drug-related increases in basal expenditure.

Preclinical models allow more controlled assessment, with rodent studies consistently demonstrating increased oxygen consumption and heat production with combined GLP-1/glucagon agonists. Translation to humans requires careful study design, ideally including weight-matched controls or eucaloric feeding protocols to isolate expenditure effects. Current evidence supports a meaningful but not fully quantified contribution of enhanced energy expenditure to triple agonist efficacy.

Implications for Future Research Directions

The energy expenditure mechanisms of triple agonism open several research avenues. Optimizing the receptor balance—whether equal agonism at all three targets or biased signaling—may further enhance metabolic outcomes. Combination with other thermogenic approaches, such as selective β3-adrenergic agonists or mitochondrial uncouplers, represents a theoretical but unexplored strategy.

Understanding interindividual variability in thermogenic response could enable personalized dosing. BAT activity varies substantially between individuals, influenced by age, adiposity, and prior cold acclimation. Identifying predictors of enhanced energy expenditure response would improve patient selection and trial design. Additionally, long-term adaptations to sustained triple agonism require characterization, as compensatory reductions in metabolic rate could attenuate initial benefits.